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Abstract
Background: Time-trend studies on psychotropic drugs among children and adolescents are scarce, and most of
them are outdated. The purpose of this study was to study prevalences of psychotropic drug use during 2004–2014
among Norwegians aged <18 years, overall and in psychotropic sub-groups.
Methods: Data were obtained from the Norwegian Prescription Database, which covers all dispensed prescription
drugs in Norway from 2004 and onwards. Psychotropic drugs included: antipsychotics (ATC-group N05A), anxiolytics
(N05B), hypnotic/sedatives (N05C), antidepressants (N06A), stimulants (N06BA), and alimemazine (R06AD01).
Period (1-year) prevalence of use, overall and in subgroups of psychotropic drugs, was estimated by identifying
individuals <18 years who had at least one psychotropic drug dispensed during each year.
Results: Psychotropic drug use increased in 0–17 year olds over an 11-year period, in which the main contributing drugs
were stimulants (boys overall; 15.0 to 20.8/1000, girls overall; 3.8 to 8.5/1000), hypnotic/sedative drugs in adolescents
(boys overall; 4.2 to 10.8/1000, girls overall; 2.6 to 8.8/1000) and to some extent antidepressants among adolescent girls
(girls overall from 3.1 to 4.0/1000). Psychotropic drug use was, however, reduced by half in the youngest children,
attributed to reduction of alimemazine only (1-year olds: boys; from 36.6 to 10.2/1000, girls; 26.9 to 7.2/1000). A higher
level of psychotropic drug use was observed among younger boys, but there is a shift towards girls using more
psychotropic drugs than boys during adolescence for all psychotropic drugs except for stimulants.
Conclusion: Different trends in psychotropic drug use exist in age and gender subgroups. Psychotropic drug use has
decreased among the youngest children, attributed to alimemazine, and increased in older children and adolescents,
attributed mainly to stimulants and hypnotics/sedatives.
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Background
Time-trend studies on psychotropic drugs among chil-
dren and adolescents are scarce, and most of them are
outdated. Overall, there seem to be similar trends of
increasing use of psychotropic drugs in children and
adolescents in the recent past in European countries
[1], Netherlands (1995–2000) [2], Denmark (1996–2010)
[3], Iceland (2003–2007) [4] and Norway (2004–2010 in
15–16 year olds) [5]. In parallel, psychotropic drug use in
the US among children and adolescents increased twofold
to threefold from 1984 to 1996, and increased further
between 2000 and 2002 [1, 6].
The increase has been attributed to use of stimulants
in particular, as observed in European countries [2–4, 7, 8].
However, although there has been a trend of increasing use
of stimulants, the level of use varies substantially between
countries. For example, in a Nordic comparison study,
Zoega et al. documented that 7–15 year old Icelanders were
nearly five times more likely than Finnish children at the
same age to have used ADHD drugs in 2007 [9].
Time trends for use of antidepressants vary between
countries. For example, whereas an increasing use of
antidepressants among 0–17 year olds is observed in
Denmark between 1995 and 2011 [3, 10], use in this
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age-group decreased in Iceland in the period 2003–2007
[4]. A trend of increasing use of antidepressants was
observed in Canada between 2005 and 2009 [11].
Antipsychotic drug use among 0–17 year olds has also
been increasing in Iceland (up to 2007) [4], and Denmark
(up to 2010) [3], but at a higher level in Iceland. An
increase has also been observed in Canada up to 2010
[12, 13].
Time-trend studies on the use of hypnotic drugs in
children and adolescents are scarce, since many studies
of psychotropic drugs in children and adolescents exclude
hypnotic drugs. The few published studies so far reveal a
trend of increasing use [4, 14]. For example, overall, hyp-
notic drug use among 0–17 year old Norwegians increased
in the period 2004–2011, due to an increasing use of
melatonin in particular [14]. In parallel, use of the sedative
antihistamine alimemazine declined in 0–17 year old
Norwegians in the period [14]. In Norway alimemazine
is licensed for use as a hypnotic drug in children aged
2 years and older, and has long been used for childhood
insomnia in Norway [15, 16].
Anxiolytics is one of the psychotropic subgroups pre-
scribed more seldom to children and adolescents, and
the few studies published show no large changes in pre-
scribing over time [3, 4].
Considering the lack of up-to-date information on psy-
chotropic drug use, and the focus on off-label use by
children and adolescents, new studies on psychotropic
drug use by this population are warranted. For example,
in 2004–05 European (European Medicines Agency,
EMA) and US (Food and Drug Administration, FDA) drug
medical agencies issued warnings against the use of anti-
depressants in youths [17, 18], which emphasize the need
for pharmacoepidemiological studies in the post-warning
period.
The nationwide Norwegian Prescription Database
(NorPD) captures completely dispensed drugs on an indi-
vidual level as prescribed to patients in ambulatory care
[19]. The aims of this study were to examine the preva-
lence of and trends in psychotropic drug use in the period
2004–2014, overall and in psychotropic drug subgroups
in the entire population of Norway aged <18 years.
Methods
Data source: the Norwegian prescription database
Prescription data on psychotropic drugs in 2004–2014
were drawn from NorPD which covers the entire nation
(5.1 million inhabitants) [19]. From January 2004, all
Norwegian pharmacies have been obliged to submit data
electronically to the Norwegian Institute of Public Health
on all prescribed drugs (irrespective of reimbursement)
dispensed to individuals in ambulatory care. The drugs
are classified according to the Anatomical Therapeutic
Chemical (ATC) classification system [20]. Anonymous
data collected for our study were patients’ unique identity
number (encrypted), sex, age, the year of dispensing, and
drug information (ATC code). All prescription data in
Norway is publicly available, with possibilities to create re-
ports on the number of users of a particular drug or drug
group. The data can be split by sex, 5-year age groups and
geography [19]. The data collected for this study included
age on all individuals as a variable, and data access was
granted by the Norwegian Institute of Public Health. Use
of anonymous register-data does not require any approval
from the Regional Committees for Medical and Health
Research Ethics, or notification to the Norwegian Data
Inspectorate or Data Protection Officer [19].
Our study sample comprised all Norwegian inhabitants
below 18 years of age (1.1 million), registered with a valid
personal identity number in NorPD. Information was
retrieved for the period 2004 to 2013 on the use of all
relevant psychotropic drugs: antipsychotics (ATC-group
N05A), anxiolytics (N05B), hypnotic/sedative drugs
(N05C), antidepressants (N06A), centrally acting sym-
pathomimetics, referred to as stimulants (N05BA),
and alimemazine (R06AD01). The systemic antihistamine
alimemazine is licensed in Norway for use as a supple-
ment to behavioural therapy in childhood insomnia for
children aged 2 years and older, and has been available on
the market in Norway since 1975 [21]. It has for a long
time been prescribed relatively frequently to young chil-
dren for sleep problems [15, 16, 22]. It is on this basis that
alimemazine was included. All these drug subgroups will
be referred to as ‘psychotropic drugs’.
Analyses and statistics
Period (1-year) prevalence of the use of psychotropic
drugs, overall and in subgroups of psychotropic drugs,
was estimated by identifying individuals <18 years who
had at least one psychotropic drug dispensed during
each year. One-year prevalence for psychotropic drugs
overall was calculated by identifying individuals who had
at least one psychotropic drug dispensed from any of the
included psychotropic drug subgroups, and individuals
were not counted more than once even if they had mul-
tiple psychotropic drugs dispensed during a year. The
denominator (inhabitants <18 years) is the total number
of inhabitants in Norway per 1st of July in each year, as
registered by Statistics Norway (Table 1).
Results
Overall trends in psychotropic drug use among <18 year
olds during 2004–2014
Overall use of psychotropic drugs in 0–17 year olds in-
creased slightly in both genders; from 30.6 to 35.3 per
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thousand inhabitants among boys and from 19.2 to 25.0
per thousand inhabitants among girls (Table 1). The overall
level of psychotropic drug use was higher in boys compared
to girls in the period, attributed to higher use in male
children. However, in later adolescence the level of psy-
chotropic drug use was higher among girls (Fig. 1). In
both genders, the main contributor to the overall increase
in the period was increasing use of hypnotic/sedatives and
stimulants.
There was a decrease during the study period in over-
all use of psychotropic drugs in the youngest boys and
girls, and among 1–2 year olds in particular (Fig. 1). The
decline of psychotropic drug use in 1–2 year olds was at-
tributed to a decreased use of alimemazine, decreasing
from 36.6 to 10.2/1000 in 1-year old boys and from 26.9
to 7.2/1000 in girls in the period 2004 to 2014 (Fig. 2a).
Thus, the level of alimemazine use in the youngest chil-
dren declined towards the level of use in older age groups
(which remained stable). Use of the traditional hypnotic/
sedative drugs among 1–2 year olds remained stable in the
period in both genders.
From the age of 8 years upwards, an annual increase
in psychotropic drug use was observed in both genders
(Fig. 1). This increase in the oldest age groups was at-
tributed to an increasing use of hypnotic and sedative
drugs (Fig. 2b), stimulants (Fig. 2c), and to some extent
antidepressants (Fig. 3a) as described below.
Alimemazine: alimemazine was the only psychotropic
drug whose use decreased in the period in both
genders, most pronouncedly in boys (from 8.3 to 4.5/
1000 in boys, and 7.1 to 4.7/1000 in girls) (Table 1).
Hypnotic and sedative drugs: use of hypnotic and
sedative drugs increased twofold to threefold in both
genders in the period (from 4.2 to 10.8/1000 in boys,
and from 2.6 to 8.8/1000 in girls) (Table 1). The
increase was attributed to an annual increase for the
age group 6–17 years in both genders (Fig. 2b). Age
trends revealed higher levels of use with older age in
both genders. However, whereas use reached a peak at
the age of 10–11 in boys, there was an increase in use
with age in girls (Fig. 2b).
Stimulants: stimulants increased up to twofold during
the period (from 15.0 to 20.8/1000 in boys and 3.8 to
8.5/1000 in girls) (Table 1). However, use of stimulants
seems to have been stable in boys and girls from 2010
and onwards. From the age of 6, stimulant use increased
with increasing age, reaching a peak of 43.4/1000 in
13-year old boys in 2014 (27.9/1000 in 2004), and then
use of stimulants declined steeply towards the age of 17
(Fig. 2c). We also observed an increase in use over time
and with increasing age in girls up to 11–12 years of age,
then levelling out. The overall relative increases in
stimulant use in the period, however, were 120 %
among girls and 40 % among boys.
Table 1 One-year prevalence (per 1000 inhabitants < 18 years of age) of psychotropic drug use among 0–17 year olds a; overall and
in psychotropic drug subcategories, in the period 2004-2014
Boys 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
N= 555,198 557,821 560,169 561,730 563,373 565,599 568,891 571,362 573,463 575,654 576,584
Alimemazine (R06DA01) 8.3 7.1 7.0 7.0 5.8 5.7 6.3 5.6 4.9 4.4 4.5
Hypnotics/sedatives (N05C) 4.2 5.3 6.1 7.3 7.9 8.7 9.5 10.0 10.1 10.1 10.8
Stimulants (N06BA) 15.0 16.9 17.5 18.7 19.7 20.5 21.0 20.8 20.7 20.6 20.8
Antidepressants (N06A) 2.1 1.7 1.7 1.8 1.8 2.0 2.2 2.2 2.2 2.1 2.0
Antipsychotics (N05A) 1.6 1.8 1.9 2.0 2.2 2.3 2.3 2.4 2.3 2.2 2.2
Anxiolytics (N05B) 4.7 4.8 4.9 4.9 4.5 4.6 4.6 4.7 4.6 4.2 3.9
Total psychotropics 30.6 30.7 31.8 33.5 33.5 35.0 37.0 36.7 35.9 34.7 35.3
Girls 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
N= 527,128 530,212 532,559 534,273 535,906 537,882 540,265 543,012 544,762 547,243 548,577
Alimemazine (R06DA01) 7.1 6.4 6.4 6.4 5.3 4.9 5.5 5.5 5.1 4.6 4.7
Hypnotics/sedatives (N05C) 2.6 3.2 3.7 4.4 5.1 5.7 6.4 7.0 7.7 8.0 8.8
Stimulants (N06BA) 3.8 4.9 5.5 6.3 7.0 7.4 7.9 7.9 8.1 8.3 8.5
Antidepressants (N06A) 3.1 2.5 2.4 2.6 2.6 2.6 2.8 3.0 3.6 4.0 10.0
Antipsychotics (N05A) 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.5 1.5 1.6
Anxiolytics (N05B) 4.5 4.7 4.7 4.7 4.4 4.4 4.2 4.4 4.5 4.1 3.9
... Total psychotropics 19.2 19.0 19.7 20.9 20.7 21.1 22.9 23.6 24.5 24.2 25.0
aage composition of the overall Norwegian population aged 0–17 years did not change significantly in the period 2004–2014
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Antidepressants: the time trend in the use of
antidepressants revealed an overall decrease in use in
boys and girls from 2004 to 2005–6, followed by an
annual increase in the following years up to 2014
(Table 1). This increase was more pronounced among
girls than boys, attributed to increasing use among those
aged 15 and older (Fig. 3a). Antidepressants were used at
twice the level among adolescent girls as compared to
boys. For example, 27.9/1000 of all 17-year old girls had
at least one antidepressant prescription dispensed in
2014, compared to 11.5/1000 in boys.
Antipsychotic drugs: a relative increase in use of about
40 % was observed in the period in both genders (from
1.6 to 2.2/1000 in boys and from 1.1 to 1.65/1000 in
girls) (Table 1), attributed to an increase in use from the
age of 8 onwards (Fig. 3b). However, the prevalences of
use in girls and boys are low.
Anxiolytics: use of anxiolytics was stable in the period
(4.7-3.9/1000 in boys and 4.5-3.9/1000 in girls).
Throughout the period, overall use of anxiolytics had a
peak in 1–2 year olds in both genders (Fig. 3c). Among
1–2 year olds, 97 % of all anxiolytics dispensed were
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Fig. 1 One-year prevalence (per 1000 inhabitants <18 years of age) of psychotropic drug use, by age and gender
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rectal solutions of benzodiazepines (results not shown
in figure). Among adolescent girls, use of anxiolytics
increased from 15 years of age.
Discussion
This study revealed an overall increase in psychotropic
drug use in 0–17 year olds over a 10-year period, in
which the main contributing drugs were stimulants,
hypnotic/sedative drugs in adolescents and, to some
extent, antidepressants among girls. Psychotropic drug
use was, however, reduced by half in the youngest
children, attributed to reduction of alimemazine use.
A higher level of psychotropic drug use was observed
among younger boys, but there is a shift towards girls
using more psychotropic drugs than boys during ado-
lescence for all psychotropic drugs except stimulants.
With this study, we present the most comprehensive
nationwide analysis to date of psychotropic drug use
among children and adolescents over time. Our study
has several important strengths. First, it is based on
complete data on dispensed psychotropic drugs in out-
patient care [23]. Second, all of the drugs included in
our analysis are captured by the prescription database,
as none of the drugs are available over the counter. A
limitation is, however, that we do not have data on
whether the drugs are actually taken. Further, this study
reveals no information on indications for the psycho-
tropic drugs at an individual level, which would have
Fig. 2 One-year prevalence (per 1000 inhabitants <18 years of age) of use of alimemazine, hypnotics and sedatives, and stimulants in boys and
girls, by age
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been valuable complementary information in the discus-
sion of the observed trends in use.
Decline in use of alimemazine in young children – trend
in use is in accordance with recommendations
Since 2004, use of alimemazine has almost halved in 0–17
year olds, attributed to a decrease among 1–2 year olds in
particular, in whom use decreased more than threefold.
Alimemazine is licensed and has long been used for child-
hood insomnia in Norway [15, 16, 22].
However, frequent use of alimemazine as a hypnotic in
children has been questioned for several reasons [15].
Alimemazine is not licensed or recommended for use in
children less than 2 years old because of indications of
highly variable pharmacokinetics [24], heavy hangovers
as a commonly reported side effect [25–27], and a few
reports of fatal adverse reactions [28–32]. Although not
commonly conducted in children, a few small random-
ized controlled trials have explored the hypnotic effect
of alimemazine [33–36]. These showed that the effect
was at most small, transient and associated with a “re-
bound” phenomenon on withdrawal. Thus, alimemazine
is a much-debated drug, and a recently published paper
concluded that the documented effects and safety of use
as a hypnotic drug were inadequate to support use
among children [15]. The information on lack of efficacy
and negative side effects presented in both the media
and the scientific literature as well as that reported
directly to doctors may provide some explanation of
the reduction in the use of alimemazine in children.
Interestingly, decreased use of alimemazine among the
youngest was not compensated by increasing use of
Fig. 3 One-year prevalence (per 1000 inhabitants <18 years of age) of use of antidepressants, antipsychotics and anxiolytics in boys and girls,
by age
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alternative hypnotics/sedatives, or sedative antipsychotics,
which remained stable in the youngest children in the
period.
Increasing use of hypnotic drugs in adolescents only
A previous study has documented increasing use of hyp-
notic drugs between 2004 and 2011 in 0–17 year olds in
Norway, attributed to increasing use of melatonin [14].
The present study adds more detailed information to the
phenomenon of increasing hypnotic drug use, as it re-
veals information on trends in use over time according
to specific years of age. In summary, the increasing use
of hypnotic/sedative drugs earlier reported in the total
child and adolescent population is attributed to increas-
ing use among adolescents only, and the oldest girls in
particular. For example, their use among 17-year old
girls increased threefold from 2004 to 2013, and they
were used by 2-3 % of all 17-year old Norwegians in
2013. Thus, whereas use of alimemazine, the preferred
sedative among the youngest, decreased, use of other
hypnotics increased among adolescents. The observed
increase in hypnotic drug use in adolescents may be ex-
plained by an increasing prevalence of sleeping prob-
lems. In a Norwegian repeated cross-sectional study in
1983 and 2005, prevalence of sleep-onset difficulties
among adolescents increased during the last two decades
[37]. As that study does not cover the time period of the
present study, we cannot conclude that an increasing
prevalence of sleeping problems is the explanation. An
earlier study showed that melatonin was the main hyp-
notic drug used by adolescents in Norway [14]. A re-
cently published study exploring morbidity in adolescent
melatonin users revealed that 90 % of all long-term users
had either a psychiatric or neurological diagnosis from
the specialist health care system [38]. Thus, increasing
use of melatonin in treating secondary sleep problems
seems to be an important contributing factor in the ob-
served increase in the overall use of hypnotic drugs in
adolescents over time.
Pharmacoepidemiological studies on the use of hyp-
notic/sedative drugs in children and adolescents are
scarce, but a similar trend with increasing incidences of
use among adolescents, and frequent use of melatonin,
was observed in an Icelandic study [4]. Information re-
trieved from the Danish and Swedish prescription data-
bases reveals parallel trends in increasing melatonin use
in the age group 5–19 years [39, 40], attributed to use in
secondary sleep problems also in Denmark [41].
Use of stimulants over a 10-year span – has the incline
reached a threshold?
In several European countries and the US, increasing
use of psychotropic drugs in children and adolescents can
be explained by an increasing use of stimulants [2–4, 42].
Level of use seems to vary between countries, including
the Nordic countries [9]. In 2007, 1-year prevalence of use
in Iceland among 7–15 year olds was almost three times
higher than in Norway, and the level of use was twice that
of Denmark and Sweden [9].
There is a higher prevalence of stimulant use in boys
compared to girls, which is in accordance with studies
on prevalences of ADHD-disorders [43], and drug use
[9]. Girls are more likely to be inattentive without being
hyperactive or impulsive, compared with boys [44]. Girls
are thus less likely to show obvious problems, which
may contribute to a lower diagnosis rate among girls in
childhood [45, 46].
Interestingly, a comprehensive review of ADHD preva-
lence studies concluded that, during the past three de-
cades, prevalence estimates did not vary as a function of
time [43]. However, we observed an increase in use over
time, especially among girls, which may be explained by
increasing awareness, access to treatment or changing
clinical practices as suggested by the review [43].
Increasing use of antidepressants among adolescents –
girls in particular
In parallel to increasing use of hypnotic/sedative drugs
and stimulants, this study documents an increasing use
of antidepressants among adolescent girls in particular
in the post FDA and EMA warning period.
For example, prevalence of use among 14–17 year old
girls increased by 70 % from 2006 to 2013. Almost 3 %
of all 17-year old girls had an antidepressant dispensed
in 2013 and were 2.4 more likely to use antidepressants
compared to their male counterparts. After puberty,
the probability of being depressed is reported to be two
to three times greater for girls than for boys [47, 48]
which corresponds well with our findings of AD use in
adolescents.
Parallel trends and level of AD use over time are ob-
served in a Danish prescription database study on SSRIs;
the increase in use over time is driven by use in adoles-
cents, and among girls in particular [10]. Interestingly,
an opposite trend has been observed in Iceland, where
antidepressant use decreased among 0–17 year olds in
the period 2004 to 2007. Levels of AD use have, however,
been high in Iceland, and declined to 23 per 1000 in 2007
in the overall age-group [4]. Thus, despite trends of increas-
ing antidepressant use in Norway and Denmark, levels of
use in children and adolescents are low in comparison with
Iceland – as 2 and 4 out of every thousand Norwegian boys
and girls, respectively, in this age interval were dispensed
antidepressants in 2013. Despite increasing use of ADs,
levels of use in Europe seem low compared to Iceland and
the US [4,10,49,50]. Back in 2000, use of antidepressants
among 0–19 year olds in the US (16 per 1000) exceeded
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that of three Western European countries by at least three-
fold (1.1-5.4 per 1000) [50].
Several factors may explain increasing use. First, it
may be attributed to an increasing prevalence of mental
distress, and thus adolescents seeking help for their
problems. In line with this, an increasing proportion of
15–16 year old adolescent participants in a Norwegian
county survey reported seeking help for mental health
problems [51]. Second, increasing AD use may be due to
a more liberal prescription regime. In 2004–05, there
were warnings against use of SSRIs in this population
due to concerns about increased risk of suicidal ideation
and behaviour [17, 18], and prescription of ADs among
children and adolescents declined accordingly from 2004
to 2005 [52]. Since then, and according to a recently
published systematic review from the Cochrane Collab-
oration, newer antidepressants may be beneficial in the
treatment of depressive disorders in children and adoles-
cents, although uncertainty still exists concerning risks and
benefits [53]. From 2009, the SSRI fluoxetine was approved
for treatment of depression in children > 8 years in Norway,
and Norwegian guidelines for management of pediatric de-
pression suggest that SSRIs may be indicated in moderate/
severe depression and relapse of depression, always in con-
junction with psychosocial interventions [54].
Increasing use of antipsychotics – parallel trends to
stimulant use?
Overall, this study revealed an overall relative increase in
antipsychotic drug use of around 40 % in both genders
from 2004 to 2013, attributed to increasing use from
around the age of 8 and onwards. A parallel trend of in-
creasing antipsychotic drugs in children and adolescents
has been observed in Europe, the US, Canada, and
Australia [3, 12, 13, 55–57]. One explanation for this
could be an increasing use of antipsychotic drugs in
ADHD or autism [12, 13, 55, 58].
Anxiolytics for fever – cramps in young children
Anxiolytics were most frequently used by 1–2 year olds.
Further analysis revealed that close to all users at this age
had rectal solutions of benzodiazepines dispensed, com-
monly used to manage fever-cramps. Use of anxiolytic
drugs in 0–17 year olds in Norway is somewhat higher
than in Iceland and Denmark [4, 33].
Conclusion
Different trends in psychotropic drug use exist in age and
gender subgroups. Psychotropic drug use has decreased
among the youngest children, attributed to alimemazine,
and increased in older children and adolescents, attributed
mainly to stimulants and hypnotics/sedatives. There is a
higher level of psychotropic drug use in younger boys com-
pared to girls, but there is a shift towards girls using more
psychotropic drugs than boys during adolescence for all
psychotropic drugs except stimulants.
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